New Clinical Trial
Dimitra Bourboulia, PhD
Research Programs and Affiliations
Education & Fellowships
- Fellowship: National Cancer Institute, NIH, Bethesda, MD, 2013
- Fellowship: University of London, UK, 2007
- PhD: University of London, UK, 2004
- National Institutes of Health, 2007–2013
- University of London, UK, 1999–2007
* Cancer Biology and Cell Signaling
* Molecular mechanisms of tumor invasion and metastasis
* Prostate cancer development and progression
Languages Spoken (Other Than English)
Link to PubMed (Opens new window. Close the PubMed window to return to this page.)
Matrix Metalloproteases (MMP) are involved in tumor angiogenesis, invasion and metastasis. MMP are inhibited by a family of endogenous proteins, the Tissue Inhibitor of Metalloproteases or TIMPs. TIMP-2 is not only a natural occurring inhibitor of MMP, but also an inhibitor of tumor cell growth, migration, invasion and tumor angiogenesis, independently of MMP inhibitory activity.
Studies have suggested that MMP/TIMP balance is shifted towards MMP activation during cancer progression and metastasis. In addition, epigenetic inactivation of TIMP-2 promoter, i.e. hypermethylation, occurs in several cancers including prostate tumors leading to downregulation of TIMP-2 levels. It is, therefore, essential to determine how TIMP-2 is regulated, to mechanistically understand the tumor inhibitory effects. My current studies are focused on TIMP-2 post-translational regulation and how this regulation affects TIMP-2 anti-tumoral and anti-angiogenic properties in epithelial cancers, and in particular, urological malignancies.